Pazopanib, an orally available multi-kinase inhibitor of VEGFR, PDGFR, KIT, FGFR, as well as RAF, shows potent activity against a variety of solid tumors. Pazopanib是多重靶点抑制剂,对VEGFR1, VEGFR2,VEGFR3,PDGFR,FGFR,c-Kit 和 c-Fms的IC50分别为10 nM,30 nM,47 nM,84 nM,74 nM,140 nM和146 nM。
MorePonatinib (AP24534)是一种新型有效的作用于Abl, PDGFRα, VEGFR2, FGFR1和Src的多靶点抑制剂, IC50分别为0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM和5.4 nM。
MoreAvitinib (AC0010) a novel mutant-selective third-generation irreversible EGFR inhibitor is currently in phase I clinical trial.
More
